TRVI vs. VERU, GOSS, GLSI, CAPR, ALIM, ACET, ME, IVA, VACC, and ATOS
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Veru (VERU), Gossamer Bio (GOSS), Greenwich LifeSciences (GLSI), Capricor Therapeutics (CAPR), Alimera Sciences (ALIM), Adicet Bio (ACET), 23andMe (ME), Inventiva (IVA), Vaccitech (VACC), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical preparations" industry.
Trevi Therapeutics (NASDAQ:TRVI) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
Veru received 190 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 69.35% of users gave Veru an outperform vote while only 60.63% of users gave Trevi Therapeutics an outperform vote.
Trevi Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Veru has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 27.5% of Trevi Therapeutics shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trevi Therapeutics has a net margin of 0.00% compared to Veru's net margin of -405.04%. Trevi Therapeutics' return on equity of -31.51% beat Veru's return on equity.
Trevi Therapeutics has higher earnings, but lower revenue than Veru. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 240.00%. Veru has a consensus target price of $3.33, indicating a potential upside of 150.63%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Veru.
In the previous week, Veru had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 2 mentions for Veru and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.50 beat Veru's score of 0.31 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Summary
Trevi Therapeutics beats Veru on 11 of the 17 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
